Literature DB >> 2933142

Effect of melphalan in vitro on induction of murine suppressor T cells by ConA.

R Ophir, S Ben-Efraim.   

Abstract

The effect of treatment with melphalan in vitro on the activity of spleen cells from BALB/c mice was investigated. Incubation of spleen cells with 1.5-5 micrograms melphalan/1 X 10(7) inhibited subsequent mitogenic stimulation by ConA or PHA and the allogeneic response of BALB/c spleen cells against C57B1 target spleen cells. Incubation of spleen cells with ConA led to induction of suppressor T cells which when added to fresh cultures inhibited the allogeneic response. Preincubation of spleen cells with melphalan even at low concentrations (0.15-0.5 micrograms 1 X 10(7) cells) which do not directly affect mitogenic stimulation or allogeneic response partially inhibited the generation of suppressor T cells by ConA. Treatment with melphalan had no effect on already induced suppressor T cells as shown by incubation of spleen cells with melphalan (0.15-5 micrograms/1 X 10(7) cells) after incubation with ConA. Addition of cells treated with melphalan alone (without ConA) to fresh cultures led to an increase in the allogeneic response.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933142     DOI: 10.1007/BF00205578

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide.

Authors:  M Glaser
Journal:  Cell Immunol       Date:  1979-12       Impact factor: 4.868

2.  In vitro selective effect of melphalan on human T-cell populations.

Authors:  S Ben-Efraim; L Komlos; J Notmann; J Hart; I Halbrecht
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

Review 3.  The murine antitumor immune response and its therapeutic manipulation.

Authors:  R J North
Journal:  Adv Immunol       Date:  1984       Impact factor: 3.543

4.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.

Authors:  J C Hengst; M B Mokyr; S Dray
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

6.  In vitro effects of 4-hydroperoxycyclophosphamide on concanavalin A-induced human suppressor T cells.

Authors:  A Klajman; I Drucker; Y Manor; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  The induction of suppressor T cells by concanavalin A is independent of cellular proliferation and protein synthesis.

Authors:  F L Shand; I M Orme; J Ivanyi
Journal:  Scand J Immunol       Date:  1980       Impact factor: 3.487

9.  In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration.

Authors:  H Ozer; J W Cowens; M Colvin; A Nussbaum-Blumenson; D Sheedy
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

10.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  2 in total

1.  Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.

Authors:  S Shoval; R Ophir; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.

Authors:  S Ben-Efraim; S Shoval; R Ophir
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.